Pharma Pulse 11/29/24: The Advantages and Disadvantages of Using Compounded Medications & more

Advantages & Disadvantages of Using Compounded Medications

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss how compounded medications differ from commercially available drugs in terms of their manufacturing process, quality standards, and more.

Health Plan Design Challenges and the Impact of HSAs on Healthcare Use

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in incentivizing high-value healthcare while managing costs.

Should You Still Learn to Code in an A.I. World?

Coding boot camps once looked like the golden ticket to an economically secure future. But as that promise fades, what should you do? Keep learning, until further notice.

U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for RapiblykTM (landiolol) in the hospital critical care setting for the treatment of the severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter). The approval is based on clinical studies which demonstrated that RapiblykTM (landiolol) enables rapid management of the heart rate with minimal reduction of blood pressure. The approval will provide patients in the U.S. with a new treatment option and is an important step for AOP Health in bringing its mission to help patients and make an impact on rare diseases and critical care to the United States for the first time.

Pharmaceutical Commerce on LinkedIn

Happy Thanksgiving to all of our readers, experts, and clients!

We're so thankful for all of the voices that help Pharmaceutical Commerce be an authority in the industry.

Looking forward to finishing out 2024 strong, and continued success and growth in 2025!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs